Dr Michael Jarman

After a PhD in evolution and genetics working with the model organism Drosophila melanogaster at Sussex University (UK), Michael was a postdoctoral researcher in developmental genetics laboratories working on wingless (WNT) signal transduction and related pathways. Following this, he changed to a more in-silico role having obtained for an MSc in bioinformatics from Birkbeck College London and gained experience as a postdoctoral bioinformatician in several industry posts including working for seven years at the pharmaceutical company Novartis where he worked on a variety of projects with a large focus on biomarker identification for clinical disease to support early and late-stage drug development and patient stratification in drug target discovery . He joined the Pirbright Institute in 2022 as a senior postdoctoral bioinformatician within the Immunogenetics group as part of a Bill and Melinda Gates Foundation funded project. He works in the broad field of antibody repertoire analysis (Rep-Seq) and is involved in a large number of different projects with data from many species including the antibody repertoire produced in response to FMDV infection in cattle.